IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC
November 11th 2023As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.
LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC
November 11th 2023Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.